This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lewis, J. S. Articles by Welch, M. J. Search for Related Content PubMed PubMed Citation Articles by Lewis, J. S. Articles by Welch, M. J.

Copper-64-pyruvaldehyde-bis(N⁴-methylthiosemicarbazone) for the Prevention of Tumor Growth at Wound Sites following Laparoscopic Surgery

Monitoring Therapy Response with microPET and Magnetic Resonance Imaging¹

Mallinckrodt Institute of Radiology [J. S. L., M. J. W.], and the Department of Surgery [J. M. C., T. L. B., J. W. F.], Washington University School of Medicine, St. Louis, Missouri 63110; The Department of Chemistry, Washington University, St. Louis, Missouri 63110 [J. R. G.]; and Biomedical Imaging Research Center, Fukui Medical University, Matsuoka, Fukui 910-1193, Japan [Y. F.]

Laparoscopic colectomy for curable colon cancer may result in the development of abdominal wall implants because of disseminated disease and the favorable environment of the wound site for cell implantation. Injection of disaggregated human GW39 colon cancer cells into the hamster peritoneum represents a model of tumor spillage that may occur during dissection, manipulation, resection, and extraction of tumor during surgery in the clinical setting. Using this well-established animal model, we tested the efficacy of ⁶⁴Cu-pyruvaldehyde-bis(N⁴-methylthiosemicarbazone) (⁶⁴Cu-PTSM) in inhibiting tumor cell implantation in trocar wound sites. Anesthetized hamsters had four 5-mm trocars inserted through the anterior abdominal wall. GW39 cells (3.2 x 10⁴ cells in 0.5 ml) were injected into the peritoneum through a midline incision. Ten min later, hamsters were randomized to receive 5, 3, or 1 mCi of ⁶⁴Cu-PTSM through the same midline incision. High-resolution magnetic resonance imaging and microPET were used to monitor tumor volume and morphology after surgery. After 7 weeks, animals were sacrificed, and trocar and midline wounds were harvested for macroscopic and histological analysis. No macroscopic tumor was found in any of the group treated with 5 mCi of ⁶⁴Cu-PTSM, whereas 96% of the wound sites in the group treated with saline had macroscopic tumor growth (P < 0.001). This study demonstrates the therapeutic potential of ⁶⁴Cu-PTSM in inhibiting cancer cell implantation and growth at doses well below the maximum tolerated dose, with no signs of toxicity to the hamsters.

This article has been cited by other articles:

				M. Nahrendorf, H. Zhang, S. Hembrador, P. Panizzi, D. E. Sosnovik, E. Aikawa, P. Libby, F. K. Swirski, and R. Weissleder Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis Circulation, January 22, 2008; 117(3): 379 - 387. [Abstract] [Full Text] [PDF]

				L. Wei, J. Easmon, R. K. Nagi, B. D. Muegge, L. A. Meyer, and J. S. Lewis 64Cu-Azabicyclo[3.2.2]Nonane Thiosemicarbazone Complexes: Radiopharmaceuticals for PET of Topoisomerase II Expression in Tumors J. Nucl. Med., December 1, 2006; 47(12): 2034 - 2041. [Abstract] [Full Text] [PDF]

				R. L. Aft, J. S. Lewis, F. Zhang, J. Kim, and M. J. Welch Enhancing Targeted Radiotherapy by Copper(II)diacetyl- bis(N4-methylthiosemicarbazone) Using 2-Deoxy-D-Glucose Cancer Res., September 1, 2003; 63(17): 5496 - 5504. [Abstract] [Full Text] [PDF]